StockData

Marker Therapeutics vs TScan Therapeutics

MRKR and TCRX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How MRKR and TCRX compare

Marker Therapeutics is the larger company, worth 1.4 times as much as TScan Therapeutics ($13.9M against $10.2M).

Marker Therapeutics scores higher on the StockData Score (6 against 4 for TScan Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricMRKRTCRX
Size and price
Market cap$13.9M$10.2M
Share price$0.837$0.151
Change, 1 year−9.4%−86.3%
Change, 5 years−93.2%−98.3%
Beta (5Y)1.922.15
Employees5142
StockData Score
Total score6 (better)4
Valuation score13 (better)
Growth score00
Performance score00
Health score5 (better)1
Dividend score00
Valuation
P/S–1.4×
P/B1.1×0.1× (better)
FCF yield–−1157%
Fair value–$1.36
Margin of safety–88.9%
Growth
Revenue growth (TTM)–2.2%
Revenue growth, 5Y average48.0%56.9% (better)
Profitability
Operating margin–−1695%
Net margin–−1655%
FCF margin–−1666%
Return on equity−76.9% (better)−95.8%
Financial health
Debt / equity0.000.47 (better)
Interest coverage–−43.2×
Current ratio6.03 (better)3.37
Altman Z-score−42.52−6.31 (better)
Piotroski F-score22
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions23.8%53.5%
Held by insiders31.9%32.8%
Insider net buying, 12 months–$146K
Short interest, % of float1.6%4.4%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.